The Motley Fool

Does AstraZeneca’s share price fall make it a bargain FTSE 100 stock?

The AstraZeneca (LSE: AZN) share price is a long way from being the hardest hit in this market crash. It ended yesterday at just over 7,000p. This is down 9% from its pre-crash level on 21 February, and 11% below its all-time high of 7,878p printed in January.

However, because big FTSE 100 pharma firms have defensive qualities, and healthcare is an industry with long-term structural growth drivers, we shouldn’t expect a company like AZN to suffer as badly as stocks in more cyclical or structurally-challenged sectors. Therefore, we should ask whether AZN’s current discount share price is a bargain for a stock of its quality.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

Debased coinage

Fund manager Mark Slater — son of the late Jim Slater (author of best-selling investment book The Zulu Principle) — recently savaged companies’ “adjusted earnings per share” numbers as “a debased coinage.”

Most companies headline such numbers in their results, and most analysts and investors use them to value the business. Almost invariably, these numbers portray a more flattering picture of the company’s performance than statutory EPS.

I’ve previously suggested AstraZeneca’s adjusted EPS — it calls it ‘core’ EPS — is one of the most egregious around. Don’t get me wrong, I think AZN is a quality business with a sound strategy, but, for a good while, I’ve felt the shares have been over-valued on a true view of underlying EPS.

However, after the recent fall in the share price, do I think the valuation is now attractive?

Smoke and mirrors revisited

I last wrote about AZN after its Q3 results last year. In that article, I showed how the company books one-time gains on disposals of non-core drugs as ‘core’ operating profit. I pointed out that such disposals had increased from £0 in 2014 to £1.9bn in 2018, with the latter representing a whopping 33% of AZN’s ‘core’ operating profit for the year.

On a positive note, I suggested it looked like certain disposals for 2019 would be lower, and that what I consider true core earnings would increase for the first time in five years. We now have AZN’s 2019 results, and the table below brings the position up to date.








Statutory operating profit (£bn)







Adjustments (before gains on disposals) (£bn)







My core operating profit (£bn)







Gains on disposals (£bn)







AZN core operating profit (£bn)







Gains on disposals as % of AZN core operating profit







As you can see, gains on disposals in 2019 were indeed lower, both in absolute terms (£1.2bn), and as a percentage of AZN’s core operating profit (19%). This is a move in the right direction, so how is the company’s price-to-earnings (P/E) valuation looking today?

Getting there

AZN’s EPS for 2019 came in at $3.50 (267.2p at current exchange rates) on the company’s own core measure. It worked out at $2.75 (209.9p) on my core measure, and at $1.03 (78.6p) on a statutory basis.

At the current share price of 7,003p, this produces P/Es of 26.2 (AZN core), 33.4 (my core) and 89.1 (statutory). I believe my core number is a truer reflection of the underlying business performance than AZN’s core (and the statutory measure).

I’d want to see a P/E in the 20s on my measure before considering the stock a potential buy. This would require a lower share price or a further improvement in core EPS. For the moment, I continue to see AZN as a stock to avoid on valuation grounds.

Are you prepared for the next stock market correction (or even a bear market)?

It’s official: global stock markets have been on a tear for more than a decade, making this the longest bull market in history.

But this seemingly unstoppable run of success poses an uncomfortable question for investors: when will the current bull market finally run out of steam?

Opinions are split about whether we’re about to see a pullback — or even a bear market — in 2020. But one thing is crystal clear: right now there’s plenty of uncertainty and bad news out there!

It’s not just the threat posed by the coronavirus outbreak that could cause disruption — Trump’s ongoing trade-war with China and the UK’s Brexit trade negotiations with the EU rumble on... and then there’s the potential threat of both the German and Japanese economies entering recession...

It all adds up to a nasty cocktail with the potential to wreak havoc and send your portfolio into a tailspin.

Of course, nobody likes to see the value of their portfolio fall, but fortunately, you don’t have to go it alone. Download a FREE copy of our Bear Market Survival Guide today and discover the five steps we believe any investor can take right now to prepare for a downturn… including how you could potentially turn today’s market uncertainty to your advantage!

Click here to claim your free copy of this Motley Fool report now.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.